He told about this to the TASS agency.
“Based on the development of the Institute.
NF Gamalei, we made an intranasal form of the vaccine, which is simply injected into the nose ... And we submitted documents to the Ministry of Health of Russia to obtain permission to conduct clinical trials, "Talyansky said.
He also added that the company expects to register the drug in 6-8 months and make the nasal vaccine "available for the country's health."
As explained by the general director of the pharmaceutical company, the nasal form of Sputnik V is tolerated milder than the usual vaccine.
In August, the director of the Gamaleya Research Center for Epidemiology and Microbiology, Alexander Gintsburg, announced the completion of preclinical studies of a nasal vaccine against coronavirus and readiness to move to clinical trials.